Regeneron (REGN) Tops Q2 EPS by 75c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron Pharma (REGN) PT Raised to $305 at Barclays
August 3, 2018 5:10 AM EDTBarclays raised its price target on Regeneron Pharma (NASDAQ: REGN) to $305.00 (from $290.00) while maintaining a Underweight rating.
... MoreRegeneron Pharma (REGN) PT Raised to $385 at Cowen
August 2, 2018 3:51 PM EDTCowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $385.00 (from $350.00) while maintaining a Market Perform rating.
Analyst Phil Nadeau commented, "REGN reported Q2:18 Eylea sales of $992MM, (+0.8% Q/Q, +8% Y/Y) just below the consensus $1BE. Solid performance from other key... More
Regeneron Pharma (REGN) PT Raised to $440 at Oppenheimer on Q2 Report; 'Eylea Static Decreasing, 2H18 Product Launches'
August 2, 2018 3:27 PM EDTOppenheimer raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $410.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst Hartaj Singh notes a positive outlook on the shares, as REGN reported second quarter earnings per share and sales... More
Regeneron Pharma (REGN) PT Raised to $440 at Evercore ISI
August 2, 2018 11:48 AM EDTEvercore ISI raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $405.00) while maintaining a Outperform rating.
Analyst Josh Schimer noted strong performance across the board for product revenue and expenses. Dupixent/OUS Eylea were strongest spots.
... More